Form SC14D9C - Written communication relating to third party tender offer
August 14 2023 - 7:45AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange
Act of 1934
ZYNERBA PHARMACEUTICALS, INC.
(Name of Subject Company)
ZYNERBA PHARMACEUTICALS, INC.
(Name of Person Filing Statement)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
98986X109
(CUSIP Number of Class of Securities)
Armando Anido
Chairman and Chief Executive Officer
Zynerba Pharmaceuticals, Inc.
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(484) 581-7505
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and
Communications on Behalf of the Person Filing
Statement)
With copies to:
Rachael M. Bushey, Esq.
Jennifer L. Porter, Esq.
Goodwin Procter LLP
One Commerce Square
2005 Market St., 32nd Floor
Philadelphia, PA 19103
(445) 207-7805
x |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 5.02, 7.01 and 9.01 of
the Current Report on Form 8-K filed by Zynerba Pharmaceuticals, Inc. on August 14, 2023 (including all exhibits attached thereto and
incorporated therein by reference) is incorporated herein by reference.
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Jul 2023 to Jul 2024